Research Summary
Dr. Ron Mease has nearly three decades of experience in producing and purifying radionuclides, and in designing, synthesizing, purifying and testing radiopharmaceuticals and radiochemicals for imaging and radiotherapy.
Dr. Mease’s work has included the design and synthesis of prostate-specific membrane antigen- and prostate-specific antigen-based agents for PET, SPECT and optical prostate-cancer imaging and radiotherapy. He has prepared radio-labeled agents that include monoclonal antibody conjugates (radiometal-labeled) to small molecules (radiometal- and radiohalogen-labeled).
Working in the neuroradiology laboratory of Dr. Martin G. Pompe, Dr. Mease also leads the chemistry arm of the Johns Hopkins Small Animal Imaging Resource Program, which performs pre-clinical and translational cancer research.
His research has been funded by the National Institutes of Health, National Cancer Institute, and U.S. Department of Defense.
Clinical Trials
Learn more about clinical trials at Johns Hopkins Medicine.
Selected Publications
View all on PubMed
Ray Banerjee S, Pullambhatla M, Foss CA, Falk A, Byun Y, Nimmagadda S, Mease RC, Pomper MG. “Effect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA).” J Med Chem. 2013 Aug 8;56(15):6108-21. doi: 10.1021/jm400823w. Epub 2013 Jul 22
Kostova MB, Rosen DM, Chen Y, Mease RC, Denmeade SR. “Structural optimization, biological evaluation, and application of peptidomimetic prostate specific antigen inhibitors.” J Med Chem. 2013 Jun 13;56(11):4224-35. doi: 10.1021/jm301718c. Epub 2013 Jun 4
Ravert HT, Dorff P, Foss CA, Mease RC, Fan H, Holmquist CR, Phillips E, McCarthy DJ, Heys JR, Holt DP, Wang Y, Endres CJ, Dannals RF, Pomper MG. “Radiochemical synthesis and in vivo evaluation of [18F]AZ11637326: an agonist probe for the a7 nicotinic acetylcholine receptor.” Nucl Med Biol. 2013 Aug;40(6):731-9. doi: 10.1016/j.nucmedbio.2013.04.005. Epub 2013 May 13
Mease RC, Foss CA, Pomper MG. “PET imaging in prostate cancer: focus on prostate-specific membrane antigen.” Curr Top Med Chem. 2013;13(8):951-62
Cho SY, Gage KL, Mease RC, Senthamizhchelvan S, Holt DP, Jeffrey-Kwanisai A, Endres CJ, Dannals RF, Sgouros G, Lodge M, Eisenberger MA, Rodriguez R, Carducci MA, Rojas C, Slusher BS, Kozikowski AP, Pomper MG. “Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer.” J Nucl Med. 2012 Dec;53(12):1883-91. doi: 10.2967/jnumed.112.104661
